radiopharmaceuticals

News

FDA starts review of Lantheus’ generic Lutathera

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tu

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

News

Nucleus RadioPharma raises $56m in first round financing

There’s a new kid on the block in the fast-growing radiopharmaceuticals category, as Nucleus RadioPharma chalks up an oversubscribed Series A that raised $56 million that

News

Lilly takes POINT in radiopharma push

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.

News

Novartis eyes first-line use of Lutathera after trial win

Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben

FDA starts review of Lantheus’ generic Lutathera

BMS strikes again, with $4.1bn RayzeBio takeover bid

ESMO: Survival data mars Pluvicto prostate cancer trial

Nucleus RadioPharma raises $56m in first round financing

Lilly takes POINT in radiopharma push

Novartis eyes first-line use of Lutathera after trial win

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

radiopharmaceuticals

Editor's Picks